Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL523876

Cc1ccccc1.O=S(=O)([O-])C(F)(F)F.[Cu+]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 2/20 0.50
ACHE P22303 2/20 0.48
ALOX12 P18054 2/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.48
KCNH2 Q12809 9/20 0.45
CA9 Q16790 3/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
PTPN1 P18031 1/20 0.41
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA5A P35218 1/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL29576707 1.00 GPR3 (0.50) GPR3ACHEALOX12LMNATSHR
Trifluoromethanesulfonic Acid SCHEMBL28640172 0.96 GPR3 (0.50) GPR3ACHEALOX12LMNATSHR
Trifluoromethanesulfonic Acid SCHEMBL28131824 0.96 GPR3 (0.50) GPR3ACHEALOX12LMNATSHR
Trifluoromethanesulfonic Acid SCHEMBL19915287 0.96 GPR3 (0.50) GPR3ACHEALOX12LMNATSHR
Trifluoromethanesulfonic Acid SCHEMBL1088679 0.81 GPR3 (0.47) GPR3ACHEALOX12KCNH2CA9
Trifluoromethanesulfonic Acid SCHEMBL2851342 0.81 GPR3 (0.47) GPR3ACHEALOX12KCNH2CA9
Trifluoromethanesulfonic Acid SCHEMBL36147 0.81 GPR3 (0.47) GPR3ACHEALOX12KCNH2CA9
Trifluoromethanesulfonic Acid SCHEMBL29642024 0.81 GPR3 (0.48) GPR3ACHEKCNH2CA9CA1
Trifluoromethanesulfonic Acid SCHEMBL160986 0.81 GPR3 (0.48) GPR3ACHEKCNH2CA9CA1
Trifluoromethanesulfonic Acid SCHEMBL180454 0.80 TSHR (0.50) GPR3ACHEALOX12LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024097736-A1 PROCESSES FOR PREPARING AZOLOPYRIMIDINE COMPOUNDS ARCUS BIOSCIENCES, INC. (US) 2024-05-10 WO claimed
US-20230399343-A1 PROCESS OF MAKING CFTR MODULATORS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-12-14 US claimed
CN-117209457-A Synthesis of alpha-chiral amidine compound 四川师范大学 2023-12-12 CN claimed
WO-2023229323-A1 METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVE 일동제약(주) 2023-11-30 WO claimed
EP-4126862-A1 PROCESS FOR PREPARING A COT INHIBITOR COMPOUND GILEAD SCIENCES, INC. (US) 2023-02-08 EP claimed
US-20220389310-A1 LUMINESCENT MATERIALS AND METHODS THEREOF UNIVERSITY OF WASHINGTON (US) 2022-12-08 US claimed
CN-115397824-A Process for preparing COT inhibitor compounds 吉利德科学公司 2022-11-25 CN claimed
WO-2021202688-A1 PROCESS FOR PREPARING A COT INHIBITOR COMPOUND GILEAD SCIENCES, INC. (US) 2021-10-07 WO claimed
WO-2021062035-A1 LUMINESCENT MATERIALS AND METHODS THEREOF UNIVERSITY OF WASHINGTON (US) 2021-04-01 WO claimed
EP-2460789-B1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL CO (JP) 2017-04-19 EP claimed
US-9346686-B2 Copper-containing nanocrystals and methods of preparation therefor THE UNIVERSITY OF WESTERN ONTARIO (CA) 2016-05-24 US claimed
US-20150360967-A1 COPPER-CONTAINING NANOCRYSTALS AND METHODS OF PREPARATION THEREFOR THE UNIVERSITY OF WESTERN ONTARIO (CA) 2015-12-17 US claimed
US-9079830-B2 Method for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-07-14 US claimed
EP-2460789-A1 METHOD FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2012-06-06 EP claimed
US-20120123154-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-17 US claimed
US-20090105257-A1 AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 GLAXOSMITHKLINE LLC 2009-04-23 US claimed
WO-2005051890-A1 AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 SMITHKLINE BEECHAM CORPORATION (US) 2005-06-09 WO claimed
US-20240199579-A1 PROCESS FOR PREPARING A COT INHIBITOR COMPOUND GILEAD SCIENCES, INC. 2024-06-20 US disclosed
US-20040022986-A1 Limited-play optical media with improved shelf-life and playability GENERAL ELECTRIC COMPANY 2004-02-05 US disclosed
WO-2004010426-A2 LIMITED-PLAY OPTICAL MEDIA WITH IMPROVED SHELF-LIFE AND PLAYABILITY GENERAL ELETRIC COMPANY (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399343-A1 PROCESS OF MAKING CFTR MODULATORS CFTR, SLC26A4, TMEM109 GPR3 1023/4885ACHE 4027/4885ALOX12 2899/4885
US-20240199579-A1 PROCESS FOR PREPARING A COT INHIBITOR COMPOUND TPO, TFPI, TFPI2 GPR3 4884/4885ACHE 2120/4885ALOX12 2573/4885
US-20090105257-A1 AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 GPR65, GPR88, GPR84 GPR3 15/4885ACHE 4739/4885ALOX12 971/4885
US-20120123154-A1 METHOD FOR PRODUCING BIARYL COMPOUND AKR7A2, AOC2, CBR1 GPR3 2107/4885ACHE 2583/4885ALOX12 1046/4885
US-20220389310-A1 LUMINESCENT MATERIALS AND METHODS THEREOF TYR, GSTA2, CYBA GPR3 2806/4885ACHE 542/4885ALOX12 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.